$CNO
CNO Financial Group, Inc. Stock $cno

$cno Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000122460824000009 Filed on February 23, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.167B	$1.182B	$4.216B
YoY Change	14.3%	21.38%	17.87%
Cost Of Revenue	$631.4M		$2.318B
YoY Change	3.56%		39.79%
Gross Profit	$535.1M		$1.898B
YoY Change	30.23%		-1.07%
Gross Profit Margin	45.87%		45.02%
Selling, General & Admin			$402.0M
YoY Change			-0.94%
% of Gross Profit			21.18%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$70.40M		$267.4M
YoY Change	7.15%		-22.56%
% of Gross Profit	13.16%		14.09%
Operating Expenses	$963.8M	$1.045B	$3.573B
YoY Change	2.81%	20.11%	22.25%
Operating Profit	$74.80M		$459.5M
YoY Change	-2.09%		28.68%
Interest Expense	-$46.50M	-$79.00M	-$217.3M
YoY Change	-33.09%	65.27%	-258.61%
% of Operating Profit	-62.17%		-47.29%
Other Income/Expense, Net
YoY Change
Pretax Income	$146.2M	$46.10M	$356.8M
YoY Change	-14720.0%	-16.79%	-31.03%
Income Tax	$33.90M	$9.800M	$80.30M
% Of Pretax Income	23.19%	21.26%	22.51%
Net Earnings	$112.3M	$36.30M	$276.5M
YoY Change	-14137.5%	-16.36%	-30.32%
Net Earnings / Revenue	9.63%	3.07%	6.56%
Basic Earnings Per Share	$1.03	$0.33	$2.44
Diluted Earnings Per Share	$1.01	$0.32	$2.40
COMMON SHARES
Basic Shares Outstanding	109.0M shares	112.2M shares	113.3M shares
Diluted Shares Outstanding	110.8M shares		115.1M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$649.8M	$889.0M	$889.0M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment		$85.30M	$85.30M
YoY Change		83.05%	83.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$26.30B	$26.14B	$26.14B
YoY Change	3.79%	7.39%	7.39%
Other Assets	$886.1M	$936.2M	$936.2M
YoY Change	-10.32%	-19.67%	-19.67%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$34.94B	$35.10B	$35.10B
YoY Change	2.72%	5.29%	5.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses			$90.70M
YoY Change			82.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities			$90.70M
YoY Change			82.86%
LONG-TERM LIABILITIES
Long-Term Debt	$3.896B	$4.151B	$4.151B
YoY Change	-3.67%	6.89%	6.89%
Other Long-Term Liabilities	$908.8M	$848.8M	$848.8M
YoY Change	30.03%	22.32%	31.74%
Total Long-Term Liabilities	$4.804B	$4.999B	$4.999B
YoY Change	1.29%	9.23%	10.43%
TOTAL LIABILITIES
Total Short-Term Liabilities			$90.70M
Total Long-Term Liabilities	$4.804B	$4.999B	$4.999B
Total Liabilities	$32.57B	$32.89B	$32.89B
YoY Change	1.84%	2.97%	2.97%
SHAREHOLDERS EQUITY
Retained Earnings	$1.996B	$1.900B
YoY Change	19.22%	30.21%
Common Stock	$1.852B	$1.893B
YoY Change	-8.4%	-6.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.368B	$2.216B	$2.216B
YoY Change
Total Liabilities & Shareholders Equity	$34.94B	$35.10B	$35.10B
YoY Change	2.72%	5.29%	5.29%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$112.3M	$36.30M	$276.5M
YoY Change	-14137.5%	-16.36%	-30.32%
Depreciation, Depletion And Amortization	$70.40M		$267.4M
YoY Change	7.15%		-22.56%
Cash From Operating Activities	$94.60M	$176.7M	$582.9M
YoY Change	15.51%	9.82%	17.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$2.500M	$73.00M	$36.60M
YoY Change	-82.01%	-134.21%	-40.2%
Cash From Investing Activities	-$23.60M	$73.00M	-$872.3M
YoY Change	-94.2%	-134.21%	-51.03%
FINANCING ACTIVITIES
Cash Dividend Paid	$17.30M		$68.10M
YoY Change	1.17%		5.09%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$310.2M	56.50M	$533.5M
YoY Change	-253.56%	-60.74%	-55.51%
NET CHANGE
Cash From Operating Activities	$94.60M	176.7M	$582.9M
Cash From Investing Activities	-$23.60M	73.00M	-$872.3M
Cash From Financing Activities	-$310.2M	56.50M	$533.5M
Net Change In Cash	-$239.2M	306.2M	$244.1M
YoY Change	94.79%	235.01%	-381.22%
FREE CASH FLOW
Cash From Operating Activities	$94.60M	$176.7M	$582.9M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1768800000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	276500000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001224608
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssets
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssets
CY2022Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilities
CY2023Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilities
CY2023Q4	cno	Operating Loss Carryforward Limitation Number Of Shares Purchased By Each Right OperatingLossCarryforwardLimitationNumberOfSharesPurchasedByEachRight	0.001	shares
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-31792
CY2023	dei	Entity Registrant Name EntityRegistrantName	CNO Financial Group, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-3108137
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	11825 N. Pennsylvania Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
CY2023	dei	City Area Code CityAreaCode	(317)
CY2023	dei	Local Phone Number LocalPhoneNumber	817-6100
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2600000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	108991851	shares
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Indianapolis, Indiana
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	42900000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	56000000.0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	23699200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	23384200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	21506200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	20353400000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	96900000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	135300000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	15400000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8000000.0	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	2064100000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	1411900000	usd
CY2023Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable	128500000	usd
CY2022Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable	121600000	usd
CY2023Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	222700000	usd
CY2022Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	207900000	usd
CY2023Q4	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	3100000	usd
CY2022Q4	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	5500000	usd
CY2023Q4	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	787600000	usd
CY2022Q4	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	1134200000	usd
CY2023Q4	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	768600000	usd
CY2022Q4	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1077600000	usd
CY2023Q4	us-gaap	Other Investments OtherInvestments	1353400000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	1034700000	usd
CY2023Q4	us-gaap	Investments Investments	26140400000	usd
CY2022Q4	us-gaap	Investments Investments	24342400000	usd
CY2023Q4	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	774500000	usd
CY2022Q4	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	575700000	usd
CY2023Q4	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	114500000	usd
CY2022Q4	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	69200000	usd
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	251500000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	235600000	usd
CY2023Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	180700000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
CY2023Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1944400000	usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1770900000	usd
CY2023Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	3000000.0	usd
CY2022Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	2000000.0	usd
CY2023Q4	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4040700000	usd
CY2022Q4	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4223400000	usd
CY2023Q4	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	75400000	usd
CY2022Q4	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	65300000	usd
CY2023Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	936200000	usd
CY2022Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	1063400000	usd
CY2023Q4	us-gaap	Separate Account Assets SeparateAccountAssets	3100000	usd
CY2022Q4	us-gaap	Separate Account Assets SeparateAccountAssets	2700000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	641100000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	580800000	usd
CY2023Q4	us-gaap	Assets Assets	35102500000	usd
CY2022Q4	us-gaap	Assets Assets	33133100000	usd
CY2023Q4	us-gaap	Policyholder Funds PolicyholderFunds	15667800000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	15234200000	usd
CY2023Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11928200000	usd
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11240200000	usd
CY2023Q4	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	7400000	usd
CY2022Q4	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	11300000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	62100000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	64100000	usd
CY2023Q4	us-gaap	Unearned Premiums UnearnedPremiums	218900000	usd
CY2022Q4	us-gaap	Unearned Premiums UnearnedPremiums	235000000.0	usd
CY2023Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3100000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	2700000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	848800000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	693900000	usd
CY2023Q4	cno	Investment Borrowings InvestmentBorrowings	2189300000	usd
CY2022Q4	cno	Investment Borrowings InvestmentBorrowings	1639500000	usd
CY2023Q4	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	820800000	usd
CY2022Q4	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	1104600000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	1140500000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1138800000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	32886900000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	31364300000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109357540	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109357540	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114343070	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114343070	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1100000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1100000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1891500000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2033800000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1576800000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1957300000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1899800000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1691200000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2215600000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1768800000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35102500000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33133100000	usd
CY2023	us-gaap	Premiums Earned Net PremiumsEarnedNet	2505500000	usd
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	2499800000	usd
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	2523400000	usd
CY2023	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	1250200000	usd
CY2022	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	1179000000	usd
CY2021	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	1140200000	usd
CY2023	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	249500000	usd
CY2022	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	-163100000	usd
CY2021	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	280500000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-69300000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-17900000	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	21300000	usd
CY2023	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	300000	usd
CY2022	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-117500000	usd
CY2021	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-2200000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-135400000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	19100000	usd
CY2021	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	159000000.0	usd
CY2023	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	21300000	usd
CY2023	us-gaap	Interest Expense InterestExpense	238600000	usd
CY2022	us-gaap	Interest Expense InterestExpense	137000000.0	usd
CY2023	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	227400000	usd
CY2022	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	212800000	usd
CY2021	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	198200000	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1048300000	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	950900000	usd
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	981800000	usd
CY2023	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	3790000000	usd
CY2022	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	2760300000	usd
CY2021	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	3389100000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	356800000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	816500000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	733100000	usd
CY2023	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	80300000	usd
CY2022	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	185900000	usd
CY2021	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	162800000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	276500000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	630600000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	570300000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	113275000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115733000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128400000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.44
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.45
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.44
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115124000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117717000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131126000	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.40
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.36
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.35
CY2023	us-gaap	Net Income Loss NetIncomeLoss	276500000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	630600000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	570300000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	823600000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-6028400000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-486700000	usd
CY2023	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	367300000	usd
CY2022	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	-2971600000	usd
CY2021	cno	Other Comprehensive Income Loss Adjustment To Discount Rate For Liability For Future Policy Benefits OtherComprehensiveIncomeLossAdjustmentToDiscountRateForLiabilityForFuturePolicyBenefits	-854100000	usd
CY2023	cno	Other Comprehensive Income Loss Adjustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdjustmentToSpecificCreditRiskForMarketRiskBenefit	7400000	usd
CY2022	cno	Other Comprehensive Income Loss Adjustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdjustmentToSpecificCreditRiskForMarketRiskBenefit	-100000	usd
CY2021	cno	Other Comprehensive Income Loss Adjustment To Specific Credit Risk For Market Risk Benefit OtherComprehensiveIncomeLossAdjustmentToSpecificCreditRiskForMarketRiskBenefit	-2900000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-37900000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-60500000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	29400000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	486800000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-2996200000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	340900000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	106300000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-665200000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	73500000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	380500000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2331000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	267400000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	657000000.0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1700400000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	837700000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5484200000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	570300000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	267400000	usd
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	402400000	usd
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	66100000	usd
CY2021	cno	Stock Based Compensation StockBasedCompensation	42000000.0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3684700000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	630600000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2331000000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	180000000.0	usd
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	65000000.0	usd
CY2022	cno	Stock Based Compensation StockBasedCompensation	29500000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	380500000	usd
CY2023	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	2285200000	usd
CY2022	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	2300200000	usd
CY2021	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	2341800000	usd
CY2023	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	1328900000	usd
CY2022	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	1154500000	usd
CY2021	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	1073100000	usd
CY2023	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	205300000	usd
CY2022	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	149200000	usd
CY2021	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	142500000	usd
CY2023	cno	Insurance Policy Benefits InsurancePolicyBenefits	1611100000	usd
CY2022	cno	Insurance Policy Benefits InsurancePolicyBenefits	1635800000	usd
CY2021	cno	Insurance Policy Benefits InsurancePolicyBenefits	1661100000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	232500000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	120900000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	92800000	usd
CY2023	cno	Policy Acquisition Costs PolicyAcquisitionCosts	377900000	usd
CY2022	cno	Policy Acquisition Costs PolicyAcquisitionCosts	336000000.0	usd
CY2021	cno	Policy Acquisition Costs PolicyAcquisitionCosts	304200000	usd
CY2023	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	955900000	usd
CY2022	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	981900000	usd
CY2021	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	920800000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	59100000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	33900000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-19800000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	582900000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	495400000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	598300000	usd
CY2023	cno	Sales Of Investments SalesOfInvestments	1388600000	usd
CY2022	cno	Sales Of Investments SalesOfInvestments	3253600000	usd
CY2021	cno	Sales Of Investments SalesOfInvestments	1823600000	usd
CY2023	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	1397000000	usd
CY2022	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	1550700000	usd
CY2021	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	2880300000	usd
CY2023	cno	Purchases Of Investments PurchasesOfInvestments	3591900000	usd
CY2022	cno	Purchases Of Investments PurchasesOfInvestments	6482000000	usd
CY2021	cno	Purchases Of Investments PurchasesOfInvestments	6135200000	usd
CY2023	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-29400000	usd
CY2022	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-42400000	usd
CY2021	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-19500000	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	36600000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	61200000	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	75300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-872300000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1781300000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1526100000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13200000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13500000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21500000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	166100000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	190100000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	407800000	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	68100000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	64800000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	65700000	usd
CY2023	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	2111700000	usd
CY2022	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	3022600000	usd
CY2021	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	2405100000	usd
CY2023	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	1696200000	usd
CY2022	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	1461400000	usd
CY2021	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	1352500000	usd
CY2023	cno	Proceeds From Financing Arrangements ProceedsFromFinancingArrangements	80300000	usd
CY2022	cno	Proceeds From Financing Arrangements ProceedsFromFinancingArrangements	0	usd
CY2021	cno	Proceeds From Financing Arrangements ProceedsFromFinancingArrangements	0	usd
CY2023	cno	Payments On Financing Arrangements PaymentsOnFinancingArrangements	6200000	usd
CY2022	cno	Payments On Financing Arrangements PaymentsOnFinancingArrangements	0	usd
CY2021	cno	Payments On Financing Arrangements PaymentsOnFinancingArrangements	0	usd
CY2023	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	995500000	usd
CY2022	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	285000000.0	usd
CY2021	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	795800000	usd
CY2023	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	445800000	usd
CY2022	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	361300000	usd
CY2021	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	722400000	usd
CY2023	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	284800000	usd
CY2022	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	44400000	usd
CY2021	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	5400000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1000000.0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	533500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1199100000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	667600000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	244100000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-86800000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-260200000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	644900000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	731700000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	991900000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	889000000.0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	644900000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	731700000	usd
CY2023Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9863700000	usd
CY2022Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9153400000	usd
CY2023Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9863700000	usd
CY2022Q4	cno	Fixed Indexed Annuity Insurance Liabilities FixedIndexedAnnuityInsuranceLiabilities	9153400000	usd
CY2023	us-gaap	Ceded Premiums Written CededPremiumsWritten	195200000	usd
CY2022	us-gaap	Ceded Premiums Written CededPremiumsWritten	206200000	usd
CY2021	us-gaap	Ceded Premiums Written CededPremiumsWritten	222400000	usd
CY2023	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	409500000	usd
CY2022	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	388700000	usd
CY2021	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	371100000	usd
CY2023	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	16600000	usd
CY2022	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	18700000	usd
CY2021	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	20300000	usd
CY2023	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	21800000	usd
CY2022	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	25300000	usd
CY2021	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	26300000	usd
CY2023Q4	cno	Investments Held In Limited Partnerships And Hedge Funds InvestmentsHeldInLimitedPartnershipsAndHedgeFunds	521400000	usd
CY2023Q4	cno	Unfunded Commitmentsto Limited Partnerships UnfundedCommitmentstoLimitedPartnerships	514200000	usd
CY2023	cno	Number Of Insurance Subsidiaries That Are Members Of The Federal Home Loan Bank NumberOfInsuranceSubsidiariesThatAreMembersOfTheFederalHomeLoanBank	3	subsidiary
CY2023	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	104700000	usd
CY2022	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	33500000	usd
CY2021	cno	Interest Expense On Fhlb Borrowings InterestExpenseOnFhlbBorrowings	9800000	usd
CY2023	us-gaap	Derivatives Methods Of Accounting Nonhedging Derivatives DerivativesMethodsOfAccountingNonhedgingDerivatives	<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting for Derivatives</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fixed indexed annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period. We are generally able to change the participation rate at the beginning of each index period (typically on each policy anniversary date), subject to contractual minimums. The Company accounts for the options attributed to the policyholder for the estimated life of the contract as embedded derivatives. We are required to record the embedded derivatives related to our fixed indexed annuity products at estimated fair value. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of the embedded derivative is based on the estimated cost to fulfill our commitment to fixed indexed annuity policyholders to purchase a series of annual forward options over the duration of the policy that back the potential return based on a percentage of the amount of increase in the value of the appropriate index. In valuing these options, we are required to make assumptions regarding: (i) future index values to determine both the future notional amounts at each anniversary date and the future prices of the forward starting options; (ii) future annual participation rates; and (iii) non-economic factors related to policy persistency. These assumptions are used to estimate the future cost to purchase the options.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of the embedded derivatives is determined based on the present value of estimated future option costs discounted using a risk-free rate adjusted for our non-performance risk and risk margins for non-capital market inputs. The non-performance risk adjustment is determined by taking into consideration publicly available information related to spreads in the secondary market for debt with credit ratings similar to ours. These observable spreads are then adjusted to reflect the priority of these liabilities and the claim paying ability of the issuing insurance subsidiaries. Changes in fair value of such embedded derivatives are included in the insurance policy benefits line item in the consolidated statement of operations.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk margins are established to capture non-capital market risks which represent the additional compensation a market participant would require to assume the risks related to the uncertainties regarding the embedded derivatives, including future policyholder behavior related to persistency. The determination of the risk margin is highly judgmental given the lack of a market to assume the risks solely related to the embedded derivatives of our fixed indexed annuity products.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the appropriate risk-free rate and non-performance risk is sensitive to the economic and interest rate environment. Accordingly, the value of the derivative is volatile due to external market sensitivities, which may materially affect net income. Additionally, changes in the judgmental assumptions regarding the appropriate risk margin can significantly impact the value of the derivative.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income.</span></div>
CY2021Q1	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	259600000	usd
CY2021Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1485800000	usd
CY2021Q1	us-gaap	Reinsurance Recoverables Gross ReinsuranceRecoverablesGross	4728400000	usd
CY2021Q1	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	2500000	usd
CY2021Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	806400000	usd
CY2021Q1	us-gaap	Policyholder Funds PolicyholderFunds	12367700000	usd
CY2021Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	15704900000	usd
CY2021Q1	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	114800000	usd
CY2021Q1	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	91700000	usd
CY2021	cno	Gross Investment Income Insurance Entity Fixed Maturities GrossInvestmentIncomeInsuranceEntityFixedMaturities	962600000	usd
CY2023	cno	Gross Investment Income Insurance Entity Equity Securities GrossInvestmentIncomeInsuranceEntityEquitySecurities	1700000	usd
CY2022	cno	Gross Investment Income Insurance Entity Equity Securities GrossInvestmentIncomeInsuranceEntityEquitySecurities	5900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	23699200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	21506200000	usd
CY2023Q4	cno	Available For Sale Securities Fair Value Disclosure Percentage Of Estimated Fair Value AvailableForSaleSecuritiesFairValueDisclosurePercentageOfEstimatedFairValue	1.000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	202100000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	193300000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	2288200000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	2191700000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1630400000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1546400000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	12263300000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	10750300000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	16384000000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	14681700000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	7315200000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	6824500000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	23699200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	21506200000	usd
CY2023	cno	Gross Investment Income Insurance Entity Fixed Maturities GrossInvestmentIncomeInsuranceEntityFixedMaturities	1142900000	usd
CY2022	cno	Gross Investment Income Insurance Entity Fixed Maturities GrossInvestmentIncomeInsuranceEntityFixedMaturities	1084100000	usd
CY2021	cno	Gross Investment Income Insurance Entity Equity Securities GrossInvestmentIncomeInsuranceEntityEquitySecurities	4300000	usd
CY2023	cno	Gross Investment Income Insurance Entity Mortgage Loans On Real Estate GrossInvestmentIncomeInsuranceEntityMortgageLoansOnRealEstate	97400000	usd
CY2022	cno	Gross Investment Income Insurance Entity Mortgage Loans On Real Estate GrossInvestmentIncomeInsuranceEntityMortgageLoansOnRealEstate	63000000.0	usd
CY2021	cno	Gross Investment Income Insurance Entity Mortgage Loans On Real Estate GrossInvestmentIncomeInsuranceEntityMortgageLoansOnRealEstate	65000000.0	usd
CY2023	cno	Gross Investment Income Insurance Entity Policy Loans GrossInvestmentIncomeInsuranceEntityPolicyLoans	8600000	usd
CY2022	cno	Gross Investment Income Insurance Entity Policy Loans GrossInvestmentIncomeInsuranceEntityPolicyLoans	8400000	usd
CY2021	cno	Gross Investment Income Insurance Entity Policy Loans GrossInvestmentIncomeInsuranceEntityPolicyLoans	8200000	usd
CY2023	cno	Gross Investment Income Insurance Entity Other Invested Assets GrossInvestmentIncomeInsuranceEntityOtherInvestedAssets	8200000	usd
CY2022	cno	Gross Investment Income Insurance Entity Other Invested Assets GrossInvestmentIncomeInsuranceEntityOtherInvestedAssets	38000000.0	usd
CY2021	cno	Gross Investment Income Insurance Entity Other Invested Assets GrossInvestmentIncomeInsuranceEntityOtherInvestedAssets	124800000	usd
CY2023	cno	Gross Investment Income Insurance Entity Cash And Cash Equivalents GrossInvestmentIncomeInsuranceEntityCashAndCashEquivalents	20900000	usd
CY2022	cno	Gross Investment Income Insurance Entity Cash And Cash Equivalents GrossInvestmentIncomeInsuranceEntityCashAndCashEquivalents	5900000	usd
CY2021	cno	Gross Investment Income Insurance Entity Cash And Cash Equivalents GrossInvestmentIncomeInsuranceEntityCashAndCashEquivalents	300000	usd
CY2023	cno	Gross Investment Income Insurance Entity Trading Securities GrossInvestmentIncomeInsuranceEntityTradingSecurities	6500000	usd
CY2022	cno	Gross Investment Income Insurance Entity Trading Securities GrossInvestmentIncomeInsuranceEntityTradingSecurities	7700000	usd
CY2021	cno	Gross Investment Income Insurance Entity Trading Securities GrossInvestmentIncomeInsuranceEntityTradingSecurities	7200000	usd
CY2023	cno	Gross Investment Income Insurance Entity Option Income Loss GrossInvestmentIncomeInsuranceEntityOptionIncomeLoss	-48300000	usd
CY2022	cno	Gross Investment Income Insurance Entity Option Income Loss GrossInvestmentIncomeInsuranceEntityOptionIncomeLoss	-6300000	usd
CY2021	cno	Gross Investment Income Insurance Entity Option Income Loss GrossInvestmentIncomeInsuranceEntityOptionIncomeLoss	212000000.0	usd
CY2023	cno	Gross Investment Income Insurance Entity Increase Decrease In Value Of Options GrossInvestmentIncomeInsuranceEntityIncreaseDecreaseInValueOfOptions	177300000	usd
CY2022	cno	Gross Investment Income Insurance Entity Increase Decrease In Value Of Options GrossInvestmentIncomeInsuranceEntityIncreaseDecreaseInValueOfOptions	-200300000	usd
CY2021	cno	Gross Investment Income Insurance Entity Increase Decrease In Value Of Options GrossInvestmentIncomeInsuranceEntityIncreaseDecreaseInValueOfOptions	8900000	usd
CY2023	cno	Gross Investment Income Insurance Entity Other Specialpurpose Portfolios GrossInvestmentIncomeInsuranceEntityOtherSpecialpurposePortfolios	114000000.0	usd
CY2022	cno	Gross Investment Income Insurance Entity Other Specialpurpose Portfolios GrossInvestmentIncomeInsuranceEntityOtherSpecialpurposePortfolios	35800000	usd
CY2021	cno	Gross Investment Income Insurance Entity Other Specialpurpose Portfolios GrossInvestmentIncomeInsuranceEntityOtherSpecialpurposePortfolios	52400000	usd
CY2023	cno	Gross Investment Income Insurance Entity GrossInvestmentIncomeInsuranceEntity	1529200000	usd
CY2022	cno	Gross Investment Income Insurance Entity GrossInvestmentIncomeInsuranceEntity	1042200000	usd
CY2021	cno	Gross Investment Income Insurance Entity GrossInvestmentIncomeInsuranceEntity	1445700000	usd
CY2023	cno	Investment Income Insurance Entity Investment Expense InvestmentIncomeInsuranceEntityInvestmentExpense	29500000	usd
CY2022	cno	Investment Income Insurance Entity Investment Expense InvestmentIncomeInsuranceEntityInvestmentExpense	26300000	usd
CY2021	cno	Investment Income Insurance Entity Investment Expense InvestmentIncomeInsuranceEntityInvestmentExpense	25000000.0	usd
CY2023	us-gaap	Net Investment Income NetInvestmentIncome	1499700000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	1015900000	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1420700000	usd
CY2023Q4	cno	Carrying Value Of Fixed Maturity Investments Not Accruing Investment Income CarryingValueOfFixedMaturityInvestmentsNotAccruingInvestmentIncome	10000000	usd
CY2023Q4	cno	Carrying Value Mortgage Loans Not Accruing Investment Income CarryingValueMortgageLoansNotAccruingInvestmentIncome	2500000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-69300000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-17900000	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	21300000	usd
CY2023	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	8100000	usd
CY2022	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-52600000	usd
CY2021	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	12200000	usd
CY2023	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	400000	usd
CY2022	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-2900000	usd
CY2021	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-7300000	usd
CY2023	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-8200000	usd
CY2022	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-62000000.0	usd
CY2021	cno	Increase Decrease In Fair Value Of Other Securities IncreaseDecreaseInFairValueOfOtherSecurities	-7100000	usd
CY2023	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	300000	usd
CY2022	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-117500000	usd
CY2021	cno	Other Investments Gain Loss OtherInvestmentsGainLoss	-2200000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-69000000.0	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-135400000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	19100000	usd
CY2023	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	2400000	usd
CY2022	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-1800000	usd
CY2021	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	11400000	usd
CY2023	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	100000	usd
CY2022	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-7300000	usd
CY2021	cno	Increase Decrease In Equity Securities Fvni Held At End Of Period IncreaseDecreaseInEquitySecuritiesFVNIHeldAtEndOfPeriod	-7800000	usd
CY2023	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-2000000.0	usd
CY2022	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-43300000	usd
CY2021	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-3100000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-69000000	usd
CY2023	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	8100000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-135400000	usd
CY2022	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-52600000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	19100000	usd
CY2021	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	12200000	usd
CY2023	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	712200000	usd
CY2022	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	1651500000	usd
CY2021	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	493500000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Within One Year Amortized Cost Basis With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCostBasisWithUnrealizedLosses	145800000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Within One Year Fair Value With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValueWithUnrealizedLosses	136800000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost Basis With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCostBasisWithUnrealizedLosses	1902100000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValueWithUnrealizedLosses	1799300000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost Basis With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCostBasisWithUnrealizedLosses	1039600000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValueWithUnrealizedLosses	935200000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost Basis With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCostBasisWithUnrealizedLosses	10540000000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities After Ten Years Fair Value With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValueWithUnrealizedLosses	8946600000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Amortized Cost With Unrealized Losses Subtotal AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostWithUnrealizedLossesSubtotal	13627500000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Fair Value With Unrealized Losses Subtotal AvailableForSaleSecuritiesDebtMaturitiesFairValueWithUnrealizedLossesSubtotal	11817900000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost Basis With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCostBasisWithUnrealizedLosses	5663400000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value With Unrealized Losses AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValueWithUnrealizedLosses	5119300000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Amortized Cost Basis With Unrealized Losses Total AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisWithUnrealizedLossesTotal	19290900000	usd
CY2023Q4	cno	Available For Sale Securities Debt Maturities Fair Value With Unrealized Losses Total AvailableForSaleSecuritiesDebtMaturitiesFairValueWithUnrealizedLossesTotal	16937200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1169900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	24500000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	15400000	usd
CY2023Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	38000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10886400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1365000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12056300000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1389500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	7636900000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	835200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1897500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	471600000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	9534400000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1306800000	usd
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	2200000	usd
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	6300000	usd
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	0	usd
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	900000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	7600000	usd
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	50400000	usd
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	10300000	usd
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	12300000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	56000000.0	usd
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	7700000	usd
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-7900000	usd
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	12900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	42900000	usd
CY2023Q4	cno	Available For Sale Securities Structured Securities Fair Value AvailableForSaleSecuritiesStructuredSecuritiesFairValue	6800000000	usd
CY2023Q4	cno	Available For Sale Securities Structured Securities Fair Value Percentage Of All Fixed Maturity Securities AvailableForSaleSecuritiesStructuredSecuritiesFairValuePercentageOfAllFixedMaturitySecurities	0.317
CY2023Q4	cno	Available For Sale Securities Structured Securities Amortized Cost Basis AvailableForSaleSecuritiesStructuredSecuritiesAmortizedCostBasis	7315200000	usd
CY2023Q4	cno	Available For Sale Securities Structured Securities Fair Value AvailableForSaleSecuritiesStructuredSecuritiesFairValue	6824500000	usd
CY2023Q4	cno	Available For Sale Securities Structured Securities Fair Value Percentage Of All Fixed Maturity Securities AvailableForSaleSecuritiesStructuredSecuritiesFairValuePercentageOfAllFixedMaturitySecurities	0.317
CY2023Q4	cno	Number Of Additional States Greater Than Specified Percentage Of Mortgage Loan Balance NumberOfAdditionalStatesGreaterThanSpecifiedPercentageOfMortgageLoanBalance	0	state
CY2020Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11800000	usd
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-6200000	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5600000	usd
CY2022	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	2400000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8000000.0	usd
CY2023	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	7400000	usd
CY2022Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	37200000	usd
CY2022Q4	cno	Number Of Fixed Maturity Investments In Excess Of10 Of Shareholders Equity NumberOfFixedMaturityInvestmentsInExcessOf10OfShareholdersEquity	0	investment
CY2023Q4	cno	Number Of Fixed Maturity Investments In Excess Of10 Of Shareholders Equity NumberOfFixedMaturityInvestmentsInExcessOf10OfShareholdersEquity	0	investment
CY2023	cno	Fair Value Fixed Maturity Securities Valued Using Broker Quotes Percentage FairValueFixedMaturitySecuritiesValuedUsingBrokerQuotesPercentage	0.92
CY2023Q4	us-gaap	Life Insurance Corporate Or Bank Owned Amount LifeInsuranceCorporateOrBankOwnedAmount	202900000	usd
CY2023Q4	cno	Available For Sale Fixed Maturities With Significant Unobservable Inputs Investment Grade Percent AvailableForSaleFixedMaturitiesWithSignificantUnobservableInputsInvestmentGradePercent	0.79
CY2023Q4	cno	Available For Sale Maturities With Significant Unobservable Inputs Corporate Securities Percent AvailableForSaleMaturitiesWithSignificantUnobservableInputsCorporateSecuritiesPercent	0.80
CY2023Q4	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2526900000	usd
CY2022Q4	cno	Liability For Future Policy Benefit Before Reinsurance Reserve LiabilityForFuturePolicyBenefitBeforeReinsuranceReserve	2619800000	usd
CY2023Q4	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	64800000	usd
CY2022Q4	cno	Liability For Future Policy Benefit Deferred Profit Liability LiabilityForFuturePolicyBenefitDeferredProfitLiability	55200000	usd
CY2023Q4	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	260200000	usd
CY2022Q4	cno	Liability For Future Policy Benefit Fas Reserves Excluding Policyholder LiabilityForFuturePolicyBenefitFASReservesExcludingPolicyholder	491900000	usd
CY2023Q4	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	30700000	usd
CY2022Q4	cno	Liability For Future Policy Benefits Payment For Benefits Reserve LiabilityForFuturePolicyBenefitsPaymentForBenefitsReserve	34700000	usd
CY2023Q4	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11928200000	usd
CY2022Q4	cno	Policyholder Account Balance Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	11240200000	usd
CY2022Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-54000000.0	usd
CY2021Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	86200000	usd
CY2022Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12200000	usd
CY2021Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12100000	usd
CY2022Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-41800000	usd
CY2021Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	98300000	usd
CY2023	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	-200000	usd
CY2022	cno	Market Risk Benefit Issuance Net MarketRiskBenefitIssuanceNet	-1600000	usd
CY2023	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	21300000	usd
CY2022	us-gaap	Market Risk Benefit Interest Expense MarketRiskBenefitInterestExpense	16500000	usd
CY2023	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
CY2022	us-gaap	Market Risk Benefit Attributed Fee Collected MarketRiskBenefitAttributedFeeCollected	0	usd
CY2023	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
CY2022	us-gaap	Market Risk Benefit Benefit Payment MarketRiskBenefitBenefitPayment	0	usd
CY2023	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	-13100000	usd
CY2022	us-gaap	Market Risk Benefit Increase Decrease From Interest Rate Change MarketRiskBenefitIncreaseDecreaseFromInterestRateChange	-159500000	usd
CY2023	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	5900000	usd
CY2022	us-gaap	Market Risk Benefit Increase Decrease From Equity Market Change MarketRiskBenefitIncreaseDecreaseFromEquityMarketChange	-9500000	usd
CY2023	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	-23000000.0	usd
CY2022	us-gaap	Market Risk Benefit Increase Decrease From Volatility MarketRiskBenefitIncreaseDecreaseFromVolatility	13400000	usd
CY2023	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	3800000	usd
CY2022	us-gaap	Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected	1100000	usd
CY2023	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	-13100000	usd
CY2022	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Other MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionOther	-1000000.0	usd
CY2023	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	-1500000	usd
CY2022	cno	Market Risk Benefit Increase Decrease From Future Expected Policyholder Behavior Assumption Risk Margin MarketRiskBenefitIncreaseDecreaseFromFutureExpectedPolicyholderBehaviorAssumptionRiskMargin	-4300000	usd
CY2023	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	-1500000	usd
CY2022	us-gaap	Market Risk Benefit Increase Decrease From Other Assumption MarketRiskBenefitIncreaseDecreaseFromOtherAssumption	4800000	usd
CY2023Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-63200000	usd
CY2022Q4	us-gaap	Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-41800000	usd
CY2023Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	4800000	usd
CY2022Q4	cno	Market Risk Benefit Effect Of Changes In Instrument Specific Credit Risk MarketRiskBenefitEffectOfChangesInInstrumentSpecificCreditRisk	12200000	usd
CY2023Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-68000000.0	usd
CY2022Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-54000000.0	usd
CY2023Q4	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2022Q4	us-gaap	Market Risk Benefit Reinsurance Recoverable After Allowance MarketRiskBenefitReinsuranceRecoverableAfterAllowance	0	usd
CY2023Q4	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-68000000.0	usd
CY2022Q4	us-gaap	Market Risk Benefit After Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change MarketRiskBenefitAfterReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange	-54000000.0	usd
CY2023Q4	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	75400000	usd
CY2022Q4	us-gaap	Market Risk Benefit Asset Amount MarketRiskBenefitAssetAmount	65300000	usd
CY2023Q4	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	7400000	usd
CY2022Q4	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	11300000	usd
CY2023Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-68000000.0	usd
CY2022Q4	us-gaap	Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk	-54000000.0	usd
CY2023Q4	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	44300000	usd
CY2022Q4	us-gaap	Market Risk Benefit Net Amount At Risk MarketRiskBenefitNetAmountAtRisk	69700000	usd
CY2023	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P69Y
CY2022	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Attained Age1 NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1	P68Y
CY2023	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	2355800000	usd
CY2022	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	2361400000	usd
CY2021	us-gaap	Liability For Future Policy Benefit Gross Premium Income LiabilityForFuturePolicyBenefitGrossPremiumIncome	2409000000	usd
CY2023	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	479700000	usd
CY2022	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	474900000	usd
CY2021	us-gaap	Liability For Future Policy Benefit Interest Expense LiabilityForFuturePolicyBenefitInterestExpense	475400000	usd
CY2023Q4	us-gaap	Policyholder Funds PolicyholderFunds	15667800000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	15234200000	usd
CY2023Q4	us-gaap	Policyholder Funds PolicyholderFunds	15667800000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	15234200000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	68300000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	31800000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	64100000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	12000000.0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	154100000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	98700000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80300000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	185900000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	162800000	usd
CY2020	cno	Income Tax Expense Benefit Net Operating Loss Cares Act IncomeTaxExpenseBenefitNetOperatingLossCARESAct	-34000000	usd
CY2021Q3	cno	Tax Refund Due To Cares Act TaxRefundDueToCARESAct	80000000	usd
CY2023Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	-900000	usd
CY2022Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	8000000.0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.007
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.022
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.225
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.228
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.222
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	77100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	166000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	322800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	298500000	usd
CY2023Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	252900000	usd
CY2022Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	214800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	445500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Comprehensive Loss DeferredTaxAssetsOtherComprehensiveLoss	552400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1136400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1241500000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	36300000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	37200000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	163000000.0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	148900000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	199300000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	186100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	937100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1055400000	usd
CY2023Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	936200000	usd
CY2022Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	1063400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	937100000	usd
CY2023Q4	cno	Loss Limitation Based On Income Of Life Insurance Company LossLimitationBasedOnIncomeOfLifeInsuranceCompany	0.35
CY2023Q4	cno	Loss Limitation Based On Loss Of Non Life Entities LossLimitationBasedOnLossOfNonLifeEntities	0.35
CY2023Q4	cno	Federal Long Term Tax Exempt Rate FederalLongTermTaxExemptRate	0.0381
CY2023Q4	cno	Ownership Change Threshold Restricting Net Operating Loss Usage OwnershipChangeThresholdRestrictingNetOperatingLossUsage	0.50
CY2010Q4	cno	Ownership Percentage Threshold Relating To Company382 Provision Ownership Percentageat Which Transfersof Common Stock Become Void OwnershipPercentageThresholdRelatingToCompany382ProvisionOwnershipPercentageatWhichTransfersofCommonStockBecomeVoid	0.05
CY2009Q1	cno	Operating Loss Carryforward Limitation Numberof Rightsfor Each Share OperatingLossCarryforwardLimitationNumberofRightsforEachShare	1	right
CY2009Q1	cno	Ownership Percentage Threshold Relating To Company382 Securities OwnershipPercentageThresholdRelatingToCompany382Securities	0.0499
CY2009Q1	cno	Ownership Percentage Threshold Relating To Company382 Securities OwnershipPercentageThresholdRelatingToCompany382Securities	0.0499
CY2010Q4	cno	Ownership Percentage Threshold Relating To Company382 Provision Ownership Percentageat Which Transfersof Common Stock Become Void OwnershipPercentageThresholdRelatingToCompany382ProvisionOwnershipPercentageatWhichTransfersofCommonStockBecomeVoid	0.0499
CY2010Q4	cno	Ownership Percentage Threshold Relating To Company382 Provision Ownership Percentageat Which Transfersof Common Stock Become Void OwnershipPercentageThresholdRelatingToCompany382ProvisionOwnershipPercentageatWhichTransfersofCommonStockBecomeVoid	0.0499
CY2010Q4	cno	Ownership Percentage Threshold Relating To Company382 Provision Ownership Percentageat Which Transfersof Common Stock Become Void OwnershipPercentageThresholdRelatingToCompany382ProvisionOwnershipPercentageatWhichTransfersofCommonStockBecomeVoid	0.0499
CY2010Q4	cno	Ownership Percentage Threshold Relating To Company382 Provision Ownership Percentageat Which Transfersof Common Stock Become Void OwnershipPercentageThresholdRelatingToCompany382ProvisionOwnershipPercentageatWhichTransfersofCommonStockBecomeVoid	0.0499
CY2023Q4	cno	Nonoperating Loss Carryforwards NonoperatingLossCarryforwards	367200000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	9500000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	11200000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	1140500000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1138800000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	500000000.0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	650000000.0	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1150000000	usd
CY2023	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	LITIGATION AND OTHER LEGAL PROCEEDINGS<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2019, Bankers Conseco Life Insurance Company ("BCLIC") and Washington National commenced an action entitled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Wilmington Trust, National Association</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "Wilmington Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the Wilmington Action, BCLIC and Washington National assert claims against Wilmington Trust, National Association ("Wilmington") for breaching its express contractual obligations under four trust agreements pursuant to which Wilmington was the trustee in regard to trust assets ceded as part of reinsurance agreements with Beechwood Re Ltd. ("BRe"), as well as for breaching its fiduciary duties to BCLIC and Washington National. The Court granted Wilmington's motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On April 20, 2021, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated breach of contract and breach of fiduciary duty claims against Wilmington. The case has been resolved by settlement and dismissed.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 7, 2019, the Joint Official Liquidators of Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) and Principal Growth Strategies, LLC, commenced suit against, among others, CNO Financial Group, Inc., BCLIC, Washington National and 40\|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. On December 1, 2023, the Delaware Chancery Court lifted the stay as of November 30, 2023. On January 25, 2024, the Delaware Chancery Court granted in part and denied in part the CNO Parties’ motion to dismiss the Amended Complaint. The CNO Parties are vigorously contesting the plaintiffs’ claims.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 28, 2019, BCLIC and Washington National commenced an action entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Bankers Conseco Life Insurance Company and Washington National Insurance Company v. KPMG LLP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "KPMG Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the KPMG Action, BCLIC and Washington National assert claims against KPMG LLP ("KPMG") for aiding and abetting fraud, constructive fraud and negligent misrepresentation arising from KPMG's alleged role in the Platinum Partners' scheme to defraud BCLIC and Washington National into reinsuring its long-term care business with BRe. The Court granted KPMG’s motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On December 1, 2020, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated the aiding and abetting claim against KPMG. The case has been resolved by settlement and dismissed.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 5, 2012, plaintiffs William Jeffrey Burnett and Joe H. Camp commenced an action entitled Burnett v. Conseco Life Ins. Co. against, among others, CNO Financial Group, Inc. and CNO Services, LLC (collectively, the "CNO Entities") in the United States District Court for the Central District of California on behalf of a putative class of former interest-sensitive whole life insurance policyholders who surrendered their policies or let them lapse. Plaintiffs' first amended complaint alleges that the CNO Entities are liable under an alter ego theory for Conseco Life Insurance Company's purported breach of the optional premium payment provision (the "Optional Premium Payment") of plaintiffs' insurance policies. In January 2018, the case was transferred to the United States District Court for the Southern District of Indiana. On August 17, 2020, the Court denied the CNO Entities' motions to dismiss. On January 13, 2021, the Court granted final approval of a class action settlement between plaintiffs and co-defendant Conseco Life Insurance Company (n/k/a Wilco Life Insurance Company). The case remains pending against the CNO Entities. On March 25, 2022, the Court certified a Rule 23(b)(3) class of under 2,000 policyholders who invoked the policy's Optional Premium Payment prior to October 2008 and who surrendered their policies between October 7, 2008 and September 1, 2011. The Court's certification order acknowledged the existence of individualized issues of causation and damages, which the Court stated could be addressed in individualized proceedings following a class trial on the alter ego allegations and the meaning of the subject insurance policy language. The CNO Entities continue to vigorously defend the case.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Examinations and Fines</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guaranty Fund Assessments</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet at December 31, 2023, included: (i) accruals of $6.0 million, representing our estimate of all known assessments that will be levied against the Company's insurance subsidiaries by various state guaranty associations based on premiums written through December 31, 2023; and (ii) receivables of $9.5 million that we estimate will be recovered through a reduction in future premium taxes as a result of such assessments. At December 31, 2022, such guaranty fund assessment accruals were $6.2 million and such receivables were $10.6 million. These estimates are subject to change when the associations determine more precisely the losses that have occurred and how such losses will be allocated among the insurance companies. We recognized expense for such assessments of $2.0 million, $2.1 million and $2.7 million in 2023, 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of the employment agreements of two of the Company's former chief executive officers, certain wholly-owned subsidiaries of the Company are the guarantors of the former executives' nonqualified supplemental retirement benefits. The liability for such benefits was $19.8 million and $20.5 million at December 31, 2023 and 2022, respectively, and is included in the caption "Other liabilities" in the consolidated balance sheet.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases and Certain Other Long-Term Commitments</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space, equipment and computer software under contractual commitments or noncancellable operating lease agreements. Total expense pursuant to these agreements was $96.3 million, $86.4 million and $76.3 million in 2023, 2022 and 2021, respectively.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space for certain administrative operations under agreements that expire between 2024 and 2034. We lease sales offices in various states which are generally short-term in length with remaining lease terms expiring between 2024 and 2030. Many leases include an option to extend or renew the lease term. The exercise of the renewal option is at the Company's discretion. The operating lease liability includes lease payments related to options to extend or renew the lease term only if the Company is reasonably certain of exercising those options. In determining the present value of lease payments, the Company uses its incremental borrowing rate for borrowings secured by collateral commensurate with the terms of the underlying lease. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to our right of use assets are as follows (dollars in millions):</span></div><div style="text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for lease liabilities (non-cash transactions)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-3207"><span style="-sec-ix-hidden:f-3208">Total right of use assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our operating lease liabilities as of December 31, 2023 are as follows (dollars in millions):</span></div><div style="text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.403%"><tr><td style="width:1.0%"></td><td style="width:77.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-3220"><span style="-sec-ix-hidden:f-3221">Present value of lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.403%"><tr><td style="width:1.0%"></td><td style="width:77.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>
CY2019Q2	cno	Number Of Trust Agreements NumberOfTrustAgreements	4	trust_agreement
CY2022Q1	cno	Number Of Policyholders NumberOfPolicyholders	2000	policyholder
CY2021	cno	Deferred Compensation Arrangement With Individual Gain Loss Recognized DeferredCompensationArrangementWithIndividualGainLossRecognized	8900000	usd
CY2023Q4	us-gaap	Life Insurance Corporate Or Bank Owned Amount LifeInsuranceCorporateOrBankOwnedAmount	202900000	usd
CY2022Q4	us-gaap	Life Insurance Corporate Or Bank Owned Amount LifeInsuranceCorporateOrBankOwnedAmount	199100000	usd
CY2023	us-gaap	Life Insurance Corporate Or Bank Owned Change In Value LifeInsuranceCorporateOrBankOwnedChangeInValue	13000000	usd
CY2022	us-gaap	Life Insurance Corporate Or Bank Owned Change In Value LifeInsuranceCorporateOrBankOwnedChangeInValue	-4400000	usd
CY2023	us-gaap	Loss Contingency Undiscounted Amount Of Insurance Related Assessment Liability LossContingencyUndiscountedAmountOfInsuranceRelatedAssessmentLiability	6000000	usd
CY2023Q4	us-gaap	Loss Contingency Accrual Insurance Related Assessment Premium Tax Offset LossContingencyAccrualInsuranceRelatedAssessmentPremiumTaxOffset	9500000	usd
CY2022	us-gaap	Loss Contingency Undiscounted Amount Of Insurance Related Assessment Liability LossContingencyUndiscountedAmountOfInsuranceRelatedAssessmentLiability	6200000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual Insurance Related Assessment Premium Tax Offset LossContingencyAccrualInsuranceRelatedAssessmentPremiumTaxOffset	10600000	usd
CY2023	cno	Loss Contingency Insurance Related Assessment Expense Recognized LossContingencyInsuranceRelatedAssessmentExpenseRecognized	2000000	usd
CY2022	cno	Loss Contingency Insurance Related Assessment Expense Recognized LossContingencyInsuranceRelatedAssessmentExpenseRecognized	2100000	usd
CY2021	cno	Loss Contingency Insurance Related Assessment Expense Recognized LossContingencyInsuranceRelatedAssessmentExpenseRecognized	2700000	usd
CY2023	cno	Operating Leases And Sponsorship Agreements Expense OperatingLeasesAndSponsorshipAgreementsExpense	96300000	usd
CY2022	cno	Operating Leases And Sponsorship Agreements Expense OperatingLeasesAndSponsorshipAgreementsExpense	86400000	usd
CY2021	cno	Operating Leases And Sponsorship Agreements Expense OperatingLeasesAndSponsorshipAgreementsExpense	76300000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	26300000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	24300000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	23800000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	25500000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	62400000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	21700000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85300000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46600000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	22100000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16800000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13400000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10300000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8300000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	34600000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	105500000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14800000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	90700000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0379
CY2023Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	130900000	usd
CY2022Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	128800000	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	10100000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	-42800000	usd
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	-2600000	usd
CY2023	cno	Deferred Compensation Arrangement With Individual Gain Loss Recognized DeferredCompensationArrangementWithIndividualGainLossRecognized	-3600000	usd
CY2022	cno	Deferred Compensation Arrangement With Individual Gain Loss Recognized DeferredCompensationArrangementWithIndividualGainLossRecognized	48900000	usd
CY2021	us-gaap	Life Insurance Corporate Or Bank Owned Change In Value LifeInsuranceCorporateOrBankOwnedChangeInValue	-2700000	usd
CY2023Q4	cno	Deferred Compensation Arrangement With Individual Assumptions Used Calculating Recorded Liability Benefit Obligation Discount Rate DeferredCompensationArrangementWithIndividualAssumptionsUsedCalculatingRecordedLiabilityBenefitObligationDiscountRate	0.0500
CY2022Q4	cno	Deferred Compensation Arrangement With Individual Assumptions Used Calculating Recorded Liability Benefit Obligation Discount Rate DeferredCompensationArrangementWithIndividualAssumptionsUsedCalculatingRecordedLiabilityBenefitObligationDiscountRate	0.0525
CY2023	cno	Deferred Compensation Arrangementwith Individual Assumptions Used Calculating Recorded Liability Net Periodic Cost Discount Rate DeferredCompensationArrangementwithIndividualAssumptionsUsedCalculatingRecordedLiabilityNetPeriodicCostDiscountRate	0.0525
CY2022	cno	Deferred Compensation Arrangementwith Individual Assumptions Used Calculating Recorded Liability Net Periodic Cost Discount Rate DeferredCompensationArrangementwithIndividualAssumptionsUsedCalculatingRecordedLiabilityNetPeriodicCostDiscountRate	0.0275
CY2023Q4	cno	Deferred Compensation Arrangementwith Individual Expected Future Payments Next Twelve Months DeferredCompensationArrangementwithIndividualExpectedFuturePaymentsNextTwelveMonths	8200000	usd
CY2023Q4	cno	Deferred Compensation Arrangementwith Individual Expected Future Payments Year Two DeferredCompensationArrangementwithIndividualExpectedFuturePaymentsYearTwo	8500000	usd
CY2023Q4	cno	Deferred Compensation Arrangementwith Individual Expected Future Payments Year Three DeferredCompensationArrangementwithIndividualExpectedFuturePaymentsYearThree	8800000	usd
CY2023Q4	cno	Deferred Compensation Arrangementwith Individual Expected Future Payments Year Four DeferredCompensationArrangementwithIndividualExpectedFuturePaymentsYearFour	8900000	usd
CY2023Q4	cno	Deferred Compensation Arrangementwith Individual Expected Future Payments Year Five DeferredCompensationArrangementwithIndividualExpectedFuturePaymentsYearFive	8900000	usd
CY2023Q4	cno	Deferred Compensation Arrangementwith Individual Expected Future Payments Thereafter DeferredCompensationArrangementwithIndividualExpectedFuturePaymentsThereafter	44400000	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6200000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6300000	usd
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6000000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	10900000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	10300000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6700000	usd
CY2023Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	83000000	usd
CY2023	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	129300000	usd
CY2022	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-222700000	usd
CY2021	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	217800000	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-7800000	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	265800000	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	241300000	usd
CY2023	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	6600000	shares
CY2022	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	7600000	shares
CY2021	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	16600000	shares
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	165100000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	180000000	usd
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	402400000	usd
CY2023Q4	cno	Stock Repurchase Program Remaining Repurchase Authorized Amount StockRepurchaseProgramRemainingRepurchaseAuthorizedAmount	521800000	usd
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	67900000	usd
CY2023	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.59
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	65000000	usd
CY2022	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.55
CY2021Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	66100000	usd
CY2021	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.51
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.15
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.14
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.14
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.13
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.13
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.12
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4100000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5600000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7800000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2736000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.45
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	484000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	19.43
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2900000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	67000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.62
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2185000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.45
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11800000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2185000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11800000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3411000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.28
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	618000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.43
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3800000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	57000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.18
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2736000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.45
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15100000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2540000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	14100000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4544000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.01
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1023000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.01
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7800000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	110000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.97
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3411000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.28
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19200000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2662000	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15700000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9200000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10400000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18400000	usd
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2185000	shares
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2185000	shares
CY2009Q1	cno	Operating Loss Carryforward Limitation Numberof Rightsfor Each Share OperatingLossCarryforwardLimitationNumberofRightsforEachShare	1	right
CY2023Q4	cno	Price Per One Thousandthof A Shareof Junior Preferred Stock PricePerOneThousandthofAShareofJuniorPreferredStock	110.00
CY2023	cno	Preferred Stock Purchase Right Rights Would Become Exercisableinthe Eventany Personor Group Becomes Ownerofa Stated Percentage Percentage PreferredStockPurchaseRightRightsWouldBecomeExercisableintheEventanyPersonorGroupBecomesOwnerofaStatedPercentagePercentage	0.0499
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	276500000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	630600000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	570300000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	113275000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115733000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128400000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1849000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1984000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2726000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115124000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117717000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	131126000	shares
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1235200000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	-1247000000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-931000000.0	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-1780700000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	133400000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Changes In Discount Rate For Liability For Future Policy Benefit AccumulatedOtherComprehensiveIncomeLossChangesInDiscountRateForLiabilityForFuturePolicyBenefit	500700000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	4800000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Changed In Instrument Specific Credit Risk For Market Risk Benefits AccumulatedOtherComprehensiveIncomeLossChangedInInstrumentSpecificCreditRiskForMarketRiskBenefits	12200000	usd
CY2023Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	451200000	usd
CY2022Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	557500000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1576800000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1957300000	usd
CY2023	us-gaap	Direct Premiums Written DirectPremiumsWritten	4574900000	usd
CY2022	us-gaap	Direct Premiums Written DirectPremiumsWritten	4619700000	usd
CY2021	us-gaap	Direct Premiums Written DirectPremiumsWritten	4457700000	usd
CY2023	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	16600000	usd
CY2022	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	18600000	usd
CY2021	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	20700000	usd
CY2023	us-gaap	Ceded Premiums Earned CededPremiumsEarned	194600000	usd
CY2022	us-gaap	Ceded Premiums Earned CededPremiumsEarned	214600000	usd
CY2021	us-gaap	Ceded Premiums Earned CededPremiumsEarned	231300000	usd
CY2023	us-gaap	Premiums Written Net PremiumsWrittenNet	4396900000	usd
CY2022	us-gaap	Premiums Written Net PremiumsWrittenNet	4423700000	usd
CY2021	us-gaap	Premiums Written Net PremiumsWrittenNet	4247100000	usd
CY2023	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-18500000	usd
CY2022	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-9800000	usd
CY2021	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-900000	usd
CY2023	cno	Premiums On Universal Life And Products Without Mortality And Morbidity Risk Additions To Insurance Liabilities PremiumsOnUniversalLifeAndProductsWithoutMortalityAndMorbidityRiskAdditionsToInsuranceLiabilities	2111700000	usd
CY2022	cno	Premiums On Universal Life And Products Without Mortality And Morbidity Risk Additions To Insurance Liabilities PremiumsOnUniversalLifeAndProductsWithoutMortalityAndMorbidityRiskAdditionsToInsuranceLiabilities	2123600000	usd
CY2021	cno	Premiums On Universal Life And Products Without Mortality And Morbidity Risk Additions To Insurance Liabilities PremiumsOnUniversalLifeAndProductsWithoutMortalityAndMorbidityRiskAdditionsToInsuranceLiabilities	1905200000	usd
CY2023	cno	Premiums Earned Traditional Products With Mortality Or Morbidity Risk PremiumsEarnedTraditionalProductsWithMortalityOrMorbidityRisk	2303700000	usd
CY2022	cno	Premiums Earned Traditional Products With Mortality Or Morbidity Risk PremiumsEarnedTraditionalProductsWithMortalityOrMorbidityRisk	2309900000	usd
CY2021	cno	Premiums Earned Traditional Products With Mortality Or Morbidity Risk PremiumsEarnedTraditionalProductsWithMortalityOrMorbidityRisk	2342800000	usd
CY2023	cno	Fees And Surrender Charges On Interest Sensitive Products FeesAndSurrenderChargesOnInterestSensitiveProducts	201800000	usd
CY2022	cno	Fees And Surrender Charges On Interest Sensitive Products FeesAndSurrenderChargesOnInterestSensitiveProducts	189900000	usd
CY2021	cno	Fees And Surrender Charges On Interest Sensitive Products FeesAndSurrenderChargesOnInterestSensitiveProducts	180600000	usd
CY2023	us-gaap	Premiums Earned Net PremiumsEarnedNet	2505500000	usd
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	2499800000	usd
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	2523400000	usd
CY2023Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	4	state
CY2023	cno	Specified Percentage Of Total Collected Premiums That State Must Exceed To Be Identified SpecifiedPercentageOfTotalCollectedPremiumsThatStateMustExceedToBeIdentified	0.05
CY2023	us-gaap	Insurance Commissions InsuranceCommissions	111100000	usd
CY2022	us-gaap	Insurance Commissions InsuranceCommissions	114200000	usd
CY2021	us-gaap	Insurance Commissions InsuranceCommissions	110900000	usd
CY2023	cno	Salaries Wages And Officers Compensation Including Share Based Compensation SalariesWagesAndOfficersCompensationIncludingShareBasedCompensation	290900000	usd
CY2022	cno	Salaries Wages And Officers Compensation Including Share Based Compensation SalariesWagesAndOfficersCompensationIncludingShareBasedCompensation	287900000	usd
CY2021	cno	Salaries Wages And Officers Compensation Including Share Based Compensation SalariesWagesAndOfficersCompensationIncludingShareBasedCompensation	267900000	usd
CY2023	cno	Operating Costs And Expenses Other OperatingCostsAndExpensesOther	646300000	usd
CY2022	cno	Operating Costs And Expenses Other OperatingCostsAndExpensesOther	548800000	usd
CY2021	cno	Operating Costs And Expenses Other OperatingCostsAndExpensesOther	603000000.0	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1048300000	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	950900000	usd
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	981800000	usd
CY2022Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1690400000	usd
CY2023	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	353500000	usd
CY2023	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	192600000	usd
CY2023Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1851300000	usd
CY2021Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1553300000	usd
CY2022	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	313500000	usd
CY2022	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	176400000	usd
CY2022Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1690400000	usd
CY2020Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1426400000	usd
CY2021	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	286900000	usd
CY2021	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	160000000.0	usd
CY2021Q4	cno	Deferred Policy Acquisition Cost Net Of Sales Inducements DeferredPolicyAcquisitionCostNetOfSalesInducements	1553300000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
CY2023	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	23000000.0	usd
CY2023Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	180700000	usd
CY2021Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	230100000	usd
CY2022	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	26400000	usd
CY2022Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	203700000	usd
CY2020Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	259600000	usd
CY2021	us-gaap	Present Value Of Future Insurance Profits Amortization Expense1 PresentValueOfFutureInsuranceProfitsAmortizationExpense1	29500000	usd
CY2021Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	230100000	usd
CY2022Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	80500000	usd
CY2023	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	24400000	usd
CY2023	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	11800000	usd
CY2023Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	93100000	usd
CY2021Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	68000000.0	usd
CY2022	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	22500000	usd
CY2022	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	10000000.0	usd
CY2022Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	80500000	usd
CY2020Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	59400000	usd
CY2021	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	17300000	usd
CY2021	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	8700000	usd
CY2021Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	68000000.0	usd
CY2023Q4	us-gaap	Present Value Of Future Insurance Profits Percentage Of Amortization Expense Year One PresentValueOfFutureInsuranceProfitsPercentageOfAmortizationExpenseYearOne	0.11
CY2023Q4	us-gaap	Present Value Of Future Insurance Profits Percentage Of Amortization Expense Year Two PresentValueOfFutureInsuranceProfitsPercentageOfAmortizationExpenseYearTwo	0.10
CY2023Q4	us-gaap	Present Value Of Future Insurance Profits Percentage Of Amortization Expense Year Three PresentValueOfFutureInsuranceProfitsPercentageOfAmortizationExpenseYearThree	0.09
CY2023Q4	us-gaap	Present Value Of Future Insurance Profits Percentage Of Amortization Expense Year Four PresentValueOfFutureInsuranceProfitsPercentageOfAmortizationExpenseYearFour	0.08
CY2023Q4	us-gaap	Present Value Of Future Insurance Profits Percentage Of Amortization Expense Year Five PresentValueOfFutureInsuranceProfitsPercentageOfAmortizationExpenseYearFive	0.07
CY2023	us-gaap	Net Income Loss NetIncomeLoss	276500000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	630600000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	570300000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	267400000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	248500000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	236600000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	21100000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	152000000.0	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	182600000	usd
CY2023	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	449700000	usd
CY2022	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-374700000	usd
CY2021	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	269000000.0	usd
CY2023	cno	Change In Accrued Investment Income And Amortization Of Premium Or Discount On Investments ChangeInAccruedInvestmentIncomeAndAmortizationOfPremiumOrDiscountOnInvestments	-170700000	usd
CY2022	cno	Change In Accrued Investment Income And Amortization Of Premium Or Discount On Investments ChangeInAccruedInvestmentIncomeAndAmortizationOfPremiumOrDiscountOnInvestments	138700000	usd
CY2021	cno	Change In Accrued Investment Income And Amortization Of Premium Or Discount On Investments ChangeInAccruedInvestmentIncomeAndAmortizationOfPremiumOrDiscountOnInvestments	-347600000	usd
CY2023	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	377900000	usd
CY2022	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	336000000.0	usd
CY2021	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	304200000	usd
CY2023	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-69000000.0	usd
CY2022	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-135400000	usd
CY2021	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	19100000	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	47800000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-99100000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	10700000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	582900000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	495400000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	598300000	usd
CY2023	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	23300000	usd
CY2022	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	25200000	usd
CY2021	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	26000000.0	usd
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	1558900000	usd
CY2022Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	1849800000	usd
CY2023Q4	cno	Statutory Accounting Practices Statutory Asset Valuation Reserve StatutoryAccountingPracticesStatutoryAssetValuationReserve	352500000	usd
CY2022Q4	cno	Statutory Accounting Practices Statutory Asset Valuation Reserve StatutoryAccountingPracticesStatutoryAssetValuationReserve	305800000	usd
CY2023Q4	cno	Statutory Accounting Practices Statutory Interest Maintenance Reserve StatutoryAccountingPracticesStatutoryInterestMaintenanceReserve	368100000	usd
CY2022Q4	cno	Statutory Accounting Practices Statutory Interest Maintenance Reserve StatutoryAccountingPracticesStatutoryInterestMaintenanceReserve	395700000	usd
CY2023Q4	cno	Statutory Capital And Surplus Asset Valuation Reserve Interest Maintenance Reserve Total StatutoryCapitalAndSurplusAssetValuationReserveInterestMaintenanceReserveTotal	2279500000	usd
CY2022Q4	cno	Statutory Capital And Surplus Asset Valuation Reserve Interest Maintenance Reserve Total StatutoryCapitalAndSurplusAssetValuationReserveInterestMaintenanceReserveTotal	2551300000	usd
CY2023Q4	cno	Investments In Upstream Affiliates Included In Statutory Capital And Surplus InvestmentsInUpstreamAffiliatesIncludedInStatutoryCapitalAndSurplus	42600000	usd
CY2022Q4	cno	Investments In Upstream Affiliates Included In Statutory Capital And Surplus InvestmentsInUpstreamAffiliatesIncludedInStatutoryCapitalAndSurplus	42600000	usd
CY2023	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	105000000	usd
CY2022	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	238000000	usd
CY2021	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	277500000	usd
CY2023	cno	Statutory Accounting Practices Net Realized Capital Gain Loss Netof Tax Includedin Statutory Net Income StatutoryAccountingPracticesNetRealizedCapitalGainLossNetofTaxIncludedinStatutoryNetIncome	-26300000	usd
CY2022	cno	Statutory Accounting Practices Net Realized Capital Gain Loss Netof Tax Includedin Statutory Net Income StatutoryAccountingPracticesNetRealizedCapitalGainLossNetofTaxIncludedinStatutoryNetIncome	-25900000	usd
CY2021	cno	Statutory Accounting Practices Net Realized Capital Gain Loss Netof Tax Includedin Statutory Net Income StatutoryAccountingPracticesNetRealizedCapitalGainLossNetofTaxIncludedinStatutoryNetIncome	-11200000	usd
CY2023	cno	Statutory Accounting Practices Pre Tax Feesand Interest Payable To Cno Or Its Nonlife Subsidiaries Includedin Statutory Net Income StatutoryAccountingPracticesPreTaxFeesandInterestPayableToCNOOrItsNonlifeSubsidiariesIncludedinStatutoryNetIncome	190100000	usd
CY2022	cno	Statutory Accounting Practices Pre Tax Feesand Interest Payable To Cno Or Its Nonlife Subsidiaries Includedin Statutory Net Income StatutoryAccountingPracticesPreTaxFeesandInterestPayableToCNOOrItsNonlifeSubsidiariesIncludedinStatutoryNetIncome	168400000	usd
CY2021	cno	Statutory Accounting Practices Pre Tax Feesand Interest Payable To Cno Or Its Nonlife Subsidiaries Includedin Statutory Net Income StatutoryAccountingPracticesPreTaxFeesandInterestPayableToCNOOrItsNonlifeSubsidiariesIncludedinStatutoryNetIncome	164200000	usd
CY2023Q4	cno	Percentage Of Statutory Capital And Surplus Available For Dividend Distribution Without Prior Approval From Regulatory Agency PercentageOfStatutoryCapitalAndSurplusAvailableForDividendDistributionWithoutPriorApprovalFromRegulatoryAgency	0.10
CY2023	cno	Amountof Dividends Paid By Insurance Subsidiaries AmountofDividendsPaidByInsuranceSubsidiaries	526500000	usd
CY2023	cno	Reinsurance Transaction Contribution Amount ReinsuranceTransactionContributionAmount	265000000	usd
CY2023	cno	Capital Contribution CapitalContribution	34400000	usd
CY2023Q4	cno	Trended Adjusted Capitalto Riskbased Capital Ratio Threshold TrendedAdjustedCapitaltoRiskbasedCapitalRatioThreshold	0.95
CY2023Q4	cno	Bermuda Class C Insurer Minimum Solvency Margin BermudaClassCInsurerMinimumSolvencyMargin	500000	usd
CY2023Q4	cno	Bermuda Class C Insurer Minimum Solvency Margin Percentage Of Assets BermudaClassCInsurerMinimumSolvencyMarginPercentageOfAssets	0.015
CY2023Q4	cno	Bermuda Class C Insurer Minimum Solvency Margin Percentage Of Enhanced Capital Requirement BermudaClassCInsurerMinimumSolvencyMarginPercentageOfEnhancedCapitalRequirement	0.25
CY2023Q4	cno	Target Capital Level Percentage TargetCapitalLevelPercentage	1.20
CY2023Q4	cno	Statutory Economic Capital And Surplus Percentage Of Enhanced Capital Requirement StatutoryEconomicCapitalAndSurplusPercentageOfEnhancedCapitalRequirement	1.50
CY2023	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2023	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2023	cno	Segment Revenues SegmentRevenues	4144600000	usd
CY2022	cno	Segment Revenues SegmentRevenues	3667000000	usd
CY2021	cno	Segment Revenues SegmentRevenues	4076100000	usd
CY2023	cno	Interest Credited InterestCredited		usd
CY2023	cno	Impact Of Forfeited Annual Forward Options Purchased Related To Fixed Indexed Annuities ImpactOfForfeitedAnnualForwardOptionsPurchasedRelatedToFixedIndexedAnnuities	-7100000	usd
CY2022	cno	Impact Of Forfeited Annual Forward Options Purchased Related To Fixed Indexed Annuities ImpactOfForfeitedAnnualForwardOptionsPurchasedRelatedToFixedIndexedAnnuities	1000000.0	usd
CY2021	cno	Impact Of Forfeited Annual Forward Options Purchased Related To Fixed Indexed Annuities ImpactOfForfeitedAnnualForwardOptionsPurchasedRelatedToFixedIndexedAnnuities	-15200000	usd
CY2023	cno	Segment Expenses SegmentExpenses	3685100000	usd
CY2022	cno	Segment Expenses SegmentExpenses	3200300000	usd
CY2021	cno	Segment Expenses SegmentExpenses	3561400000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	459500000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	466700000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	514700000	usd
CY2023	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	103400000	usd
CY2022	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	106300000	usd
CY2021	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	114300000	usd
CY2023	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	356100000	usd
CY2022	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	360400000	usd
CY2021	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	400400000	usd
CY2023	us-gaap	Revenues Revenues	4146800000	usd
CY2022	us-gaap	Revenues Revenues	3576800000	usd
CY2021	us-gaap	Revenues Revenues	4122200000	usd
CY2023	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	3790000000	usd
CY2022	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	2760300000	usd
CY2021	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	3389100000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	356800000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	816500000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	733100000	usd
CY2023	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	80300000	usd
CY2022	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	185900000	usd
CY2021	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	162800000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	276500000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	630600000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	570300000	usd
CY2023Q4	us-gaap	Assets Assets	35102500000	usd
CY2022Q4	us-gaap	Assets Assets	33133100000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	32886900000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	31364300000	usd
CY2023Q1	us-gaap	Revenues Revenues	1006000000	usd
CY2023Q2	us-gaap	Revenues Revenues	1022800000	usd
CY2023Q3	us-gaap	Revenues Revenues	947500000	usd
CY2023Q4	us-gaap	Revenues Revenues	1170500000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1000000.0	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	96100000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	215600000	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	46100000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22400000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48300000	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9800000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-800000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	73700000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	167300000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	36300000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.48
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.46
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.32
CY2022Q1	us-gaap	Revenues Revenues	842900000	usd
CY2022Q2	us-gaap	Revenues Revenues	855000000.0	usd
CY2022Q3	us-gaap	Revenues Revenues	905300000	usd
CY2022Q4	us-gaap	Revenues Revenues	973600000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	240300000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	299800000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	227900000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	48500000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56900000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66500000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000000.0	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10500000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	183400000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	233300000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	175900000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	38000000.0	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.55
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.99
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2023Q4	cno	Repaymentsof Investment Borrowings Relatedto Variable Interest Entities Amounts Duein2024 RepaymentsofInvestmentBorrowingsRelatedtoVariableInterestEntitiesAmountsDuein2024	338800000	usd
CY2023Q4	cno	Repaymentsof Investment Borrowings Relatedto Variable Interest Entities Amounts Duein2025 RepaymentsofInvestmentBorrowingsRelatedtoVariableInterestEntitiesAmountsDuein2025	158900000	usd
CY2023Q4	cno	Repaymentsof Investment Borrowings Relatedto Variable Interest Entities Amounts Duein2026 RepaymentsofInvestmentBorrowingsRelatedtoVariableInterestEntitiesAmountsDuein2026	124900000	usd
CY2023Q4	cno	Repaymentsof Investment Borrowings Relatedto Variable Interest Entities Amounts Duein2027 RepaymentsofInvestmentBorrowingsRelatedtoVariableInterestEntitiesAmountsDuein2027	89000000	usd
CY2023Q4	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities Amounts Due In2028 RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntitiesAmountsDueIn2028	95400000	usd
CY2023Q4	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities Amounts Due In2029 RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntitiesAmountsDueIn2029	14900000	usd
CY2023Q4	cno	Variable Interest Entity Amortized Cost Securities Held VariableInterestEntityAmortizedCostSecuritiesHeld	787600000	usd
CY2023Q4	cno	Variable Interest Entity Gross Unrealized Gains Fixed Maturity Securities VariableInterestEntityGrossUnrealizedGainsFixedMaturitySecurities	2500000	usd
CY2023Q4	cno	Variable Interest Entity Gross Unrealized Losses Fixed Maturity Securities VariableInterestEntityGrossUnrealizedLossesFixedMaturitySecurities	18400000	usd
CY2023Q4	cno	Variable Interest Entity Fixed Maturity Securities Allowance For Credit Loss VariableInterestEntityFixedMaturitySecuritiesAllowanceForCreditLoss	3100000	usd
CY2023Q4	cno	Variable Interest Entity Fixed Maturity Securities Fair Value VariableInterestEntityFixedMaturitySecuritiesFairValue	768600000	usd
CY2023	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-4400000	usd
CY2023	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	-6800000	usd
CY2023	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	2400000	usd
CY2023	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	6900000	usd
CY2023	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	18500000	usd
CY2022	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-8100000	usd
CY2022	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	-6300000	usd
CY2022	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-1800000	usd
CY2022	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	6300000	usd
CY2022	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	69200000	usd
CY2021	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	3600000	usd
CY2021	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	-7800000	usd
CY2021	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	11400000	usd
CY2021	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	8100000	usd
CY2021	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	70000000	usd
CY2023Q4	cno	Number Of Investments Held By Variable Interest Entities In Default NumberOfInvestmentsHeldByVariableInterestEntitiesInDefault	0	investment
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001224608-24-000009-index-headers.html	Edgar Link	pending
0001224608-24-000009-index.html	Edgar Link	pending
0001224608-24-000009.txt	Edgar Link	pending
0001224608-24-000009-xbrl.zip	Edgar Link	pending
cno-20231231.htm	Edgar Link	pending
cno-20231231.xsd	Edgar Link	pending
cno-20231231_g1.jpg	Edgar Link	pending
cno12312023ex211.htm	Edgar Link	pending
cno12312023ex231.htm	Edgar Link	pending
cno12312023ex311.htm	Edgar Link	pending
cno12312023ex312.htm	Edgar Link	pending
cno12312023ex321.htm	Edgar Link	pending
cno12312023ex322.htm	Edgar Link	pending
exhibit971clawback.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
cno-20231231_def.xml	Edgar Link	unprocessable
cno-20231231_lab.xml	Edgar Link	unprocessable
cno-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cno-20231231_htm.xml	Edgar Link	completed
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R139.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cno-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNO
CNO Financial Group, Inc. Stock $cno

2024 Q1 Form 10-K Financial Statement

#000122460824000009 Filed on February 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO CNO Financial Group, Inc. Stock $cno

2024 Q1 Form 10-K Financial Statement

#000122460824000009 Filed on February 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO
CNO Financial Group, Inc. Stock $cno